L.V. PUZYRYOVA, ZH.M. ALIMBETOV, Z.D. MAGOMEDOV

 Omsk State Medical University, Omsk

Contact details:

Puzyryova L.V. — MD, Associate Professor of the Higher Attestation Commission, Head of the Department of Pediatric Infectious Diseases

Address: 12 Lenin St., 644099 Omsk, Russian Federation, tel.: +7-913-149-12-32, e-mail: puzirevalv@mail.ru

 Helicobacter pylori (H. pylori) is a common pathogen traditionally associated with the upper digestive tract diseases. However, recent studies have shown that it may also play a role in the development of atherosclerosis and cardiovascular diseases. Timely detection and treatment of H. pylori infection can be considered an important part of preventing cardiovascular pathology.

The purpose — to evaluate the impact of Helicobacter pylori infection on the development of atherosclerosis and cardiovascular disease; to explore current ideas about its effects on lipid metabolism, the vascular wall, and systemic inflammation.

Material and methods. We reviewed the 2014–2025 Russian and international studies on the association between H. pylori and atherosclerosis. Data from clinical observations and meta-analyses of infected and uninfected patients were analyzed.

Results. We found a reliable association between chronic H. pylori infection and signs of clinical atherosclerosis and lipid metabolism disorders. Strains that contain the CagA gene are linked to increased inflammation and endothelial dysfunction. Eradication therapy can improve the lipid profile and reduce the level of inflammatory markers.

Conclusion. Thus, H. pylori infection is a significant non-traditional risk factor for atherosclerosis and cardiovascular diseases. Timely diagnosis and treatment of infection can be considered as an additional area of prevention of cardiovascular pathology, especially in patients with dyslipidemia and metabolic syndrome.

Key words: Helicobacter pylori, atherosclerosis, dyslipidemia, cardiovascular pathology, inflammation.

REFERENCES

1. Wang L., Lei J., Wang R., Li K. Non-traditional risk factors as contributors to cardiovascular disease. Rev. Cardiovasc. Med, 2023, vol. 24 (5), p. 134. DOI: 10.31083/j.rcm2405134
2. Joseph P., Leong D., McKee M., Anand S.S. et al. Reducing the global burden of cardiovascular disease. Part 1: the epidemiology and risk factors. Circulation Res, 2017, vol. 121 (6), pp. 677–694. DOI: 10.1161/CIRCRESAHA.117.308903
3. Alekyan B.G., Boytsov S.A., Manoshkina E.M., Kochergin N.A., Ganyukov V.I. National results of revascularization for acute coronary syndrome in 2023. Kardiologiia, 2024, vol. 64 (11), pp. 76–83. DOI: 10.18087/cardio.2024.11.n2733
4. Aramouni K., Assaf R.K., Azar M., Jabbour K. et al. Infection with Helicobacter pylori may predispose to atherosclerosis: role of inflammation and thickening of intima-media of carotid arteries. Front. Pharmacol, 2023, vol. 14, p. 1285754. DOI: 10.3389/fphar.2023.1285754
5. Kamyshnikova L.A., Yefremova O.A., Guseynli E.G. Modern review: Helicobacter pylori and the risk of developing coronary heart disease. Nauchnyye rezul′taty biomeditsinskikh issledovaniy, 2016, no. 3 (in Russ.), available at: https://cyberleninka.ru/article/n/sovremennyy-obzor-helicobacter-pylori-i-risk-razvitiya-ishemicheskoy-bolezni-serdtsa (accessed: 26.09.2025).
6. Wang Y.C. Medicinal plant activity on Helicobacter pylori-related diseases. World J. Gastroenterol, 2014, vol. 20 (30), pp. 10368–1082. DOI: 10.3748/wjg.v20.i30.10368
7. Huard K., Haddad K., Saada Y., Nguyen J. et al. Prevalence of Helicobacter pylori among patients undergoing coronary angiography (The HP-DAPT prevalence study). Sci. Rep., 2022, vol. 12 (1), pp. 16591. DOI: 10.1038/s41598-022-17034-0
8. Perfilova K.M., Shutova I.V., Neumoina N.V. et al. Prevalence of different variants of Helicobacter pylori genotypes in families of patients with Helicobacter-associated diseases. Zdorov′ye naseleniya i sreda obitaniya (ZNiSO), 2019, no. 12 (321) (in Russ.), available at: https://cyberleninka.ru/article/n/rasprostranennost-razlichnyh-variantov-genotipov-helicobacter-pylori-v-semyah-bolnyh-helikobakter-assotsiirovannymi-zabolevaniyami (accessed on: 29.09.2025).
9. Sgambato D., Visciola G., Ferrante E. et al. Prevalence of Helicobacter pylori infection in sexual partners of H. pylori-infected subjects: role of gastroesophageal reflux. United Eur. Gastroenterol. J, 2018, vol. 6, pp. 1470–1476. DOI: 10.1177/2050640618800628
10. Bordin D., Morozov S., Plavnik R., Bakulina N. et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in Russia: the data of real-world national multicenter trial. Helicobacter, 2022, vol. 27 (5). DOI: 10.1111/hel.12924
11. Budzyński J., Koziński M., Kłopocka M., Kubica J.M., Kubica J. Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. Clin. Res. Cardiol, 2014, vol. 103 (11), pp. 855–886. DOI: 10.1007/s00392-014-0720-4
12. Hofmann R., Bäck M. Time for routine Helicobacter pylori screening in coronary artery disease? Circulation, 2023, vol. 147 (23), pp. 1731–1733. DOI: 10.1161/CIRCULATIONAHA.123.064944
13. Chicherina E.N., Zubareva A.A. Impact of Helicobacter pylori infection on inflammatory markers and lipid profile of patients with acute coronary syndrome and concomitant diseases of the upper gastrointestinal tract. Vyatskiy meditsinskiy vestnik, 2022, no. 1 (73), available at: https://cyberleninka.ru/article/n/vliyanie-infitsirovannosti-helicobacter-pylori-na-vospalitelnye-markery-i-lipidnyy-profil-patsientov-s-ostrym-koronarnym-sindromom (accessed on: 05.10.2025).
14. Aggarwal K., Singh S., Singla A. et al. Unveiling the silent intruder: Helicobacter pylori’s Hidden link to ischemic heart disease. Cardiol. Rev, 2024. Opubl. onlayn 06.03.2024. DOI: 10.1097/CRD.0000000000000686
15. Vijayvergiya R., Vadivelu R. Role of Helicobacter pylori infection in pathogenesis of atherosclerosis. World J. Cardiol, 2015, vol. 7 (3), pp. 134–143. DOI: 10.4330/wjc.v7.i3.134
16. Chen Y., Xu C., Xu H., Chen W., Wang H. et al. Persistent Helicobacter pylori infection for more than 3 years leads to elevated serum homocysteine concentration: a retrospective cohort study based on a healthy Chinese population. J. Gastroenterol. Hepatol, 2021, vol. 36 (11), pp. 3077–3083. DOI: 10.1111/jgh.15603
17. Candelli M., Franza L., Cianci R., Pignataro G., Merra G. et al. The interplay between Helicobacter pylori and gut microbiota in non-gastrointestinal disorders: a special focus on atherosclerosis. Int. J. Mol. Sci, 2023, vol. 24 (24), p. 17520. DOI: 10.3390/ijms242417520
18. Hatakeyama M. Structure and function of Helicobacter pylori CagA, the first-identified bacterial protein involved in human cancer. Proc. Japan Academy. Series B, Phys. Biol. Sci, 2017, vol. 93 (4), pp. 196–219. DOI: 10.2183/pjab.93.013
19. Tahmina K., Hikawa N., Takahashi-Kanemitsu A. et al. Transgenically expressed Helicobacter pylori CagA in vascular endothelial cells accelerates arteriosclerosis in mice. Biochem. Biophys. Res. Commun, 2022, vol. 618, pp. 79–85. DOI: 10.1016/j.bbrc.2022.06.010
20. Wang J., Wang X., Luo H., Xie Y. et al. Extracellular vesicles in Helicobacter pylori-mediated diseases: mechanisms and therapeutic potential. Cell Commun. Signaling, 2025, vol. 23 (1), p. 79. DOI: 10.1186/s12964-025-02074-6
21. Xia X., Zhang L., Wu H. et al. CagA⁺ Helicobacter pylori, not CagA⁻ Helicobacter pylori, infection impairs endothelial function through exosome-mediated ROS formation. Front. Cardiovasc. Med, 2022, vol. 9, p. 881372. DOI: 10.3389/fcvm.2022.881372
22. Wang S., Xia Y. P., Luo X. Y., Chen S. L. et al. Exosomal CagA derived from Helicobacter pylori-infected gastric epithelial cells induces macrophage foam cell formation and promotes atherosclerosis. J. Mol. Cell. Cardiol, 2019, vol. 135, pp. 40–51. DOI: 10.1016/j.yjmcc.2019.07.011
23. Chmiela M., Gonciarz W. Molecular mimicry in Helicobacter pylori infections. World J. Gastroenterol, 2017, vol. 23 (22), pp. 3964–3977. DOI: 10.3748/wjg.v23.i22.3964
24. Maleki N., Mohammadzadeh A., Mardaneh J., Pazoki H., Nattagh-Eshtivani E. Helicobacter pylori infection and association with chronic diseases: a focus on cardiovascular disease, MASLD, and type 2 diabetes. Metabol. Open, 2025, vol. 27, p. 100385. DOI: 10.1016/j.metop.2025.100385
25. Sardarinia M., Akbarpour S., Lotfaliany M. et al. Risk factors for incidence of cardiovascular diseases and all-cause mortality in a Middle Eastern population over a decade follow-up: Tehran Lipid and Glucose Study. PLoS One, 2016, vol. 11 (12), p. e0167623. DOI: 10.1371/journal.pone.0167623
26. Su X., Zhang G., Cheng Y., Wang B. New insights into the emerging effects of inflammatory response on HDL particles structure and function. Mol. Biol. Rep, 2021, vol. 48 (7), pp. 5723–5733. DOI: 10.1007/s11033-021-06553-0
27. Martin-Nuñez G.M., Cornejo-Pareja I., Clemente-Postigo M., Tinahones F.J. Gut microbiota: the missing link between Helicobacter pylori infection and metabolic disorders? Front. Endocrinol. (Lausanne), 2021, vol. 12, pp. 639856. DOI: 10.3389/fendo.2021.639856
28. Gaonkar A., Zahiruddin Q.S., Shabil M., Menon S.V. et al. Association of Helicobacter pylori infection and risk of dyslipidemia: a systematic review and meta-analysis. JGH Open, 2025, vol. 9 (3), p. e70128. DOI: 10.1002/jgh3.70128
29. Wang X., He Q., Jin D. et al. Association between Helicobacter pylori infection and subclinical atherosclerosis: a systematic review and meta-analysis. Medicine (Baltimore), 2021, vol. 100 (46), p. e27840. DOI: 10.1097/MD.0000000000027840
30. Razeghian-Jahromi I., Elyaspour Z., Zibaeenezhad M.J., Hassanipour S. Prevalence of microorganisms in atherosclerotic plaques of coronary arteries: a systematic review and meta-analysis. Evidence-Based Compl. Alter. Med, 2022, p. 8678967. DOI: 10.1155/2022/8678967
31. Wang J.W., Tseng K.L., Hsu C.N., Liang C.M. et al. Association between Helicobacter pylori eradication and the risk of coronary heart diseases. PLoS One, 2018, vol. 13 (1), p. e0193646. DOI: 10.1371/journal.pone.0190219
32. Kanbay M., Gür G., Yücel M., Yilmaz U., Boyacioğlu S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Digestive Dis. Sci, 2005, vol. 50, pp. 1228–1231. DOI: 10.1007/s10620-005-2764-9
33. Alba C., Blanco A., Alarcón T. Antibiotic resistance in Helicobacter pylori. Curr. Opin. Infec. Dis, 2017, vol. 30, pp. 489–497. DOI: 10.1097/QCO.0000000000000396
34. Nista E.C., Pellegrino A., Giuli L., Candelli M., Schepis T. et al. Clinical implications of Helicobacter pylori antibiotic resistance in Italy: a review of the literature. Antibiotics, 2022, vol. 11, p. 1452. DOI: 10.3390/antibiotics11101452
35. Jonsson A.L., Bäckhed F. Role of gut microbiota in atherosclerosis. Nat. Rev. Cardiol, 2017, vol. 14, pp. 79–87. DOI: 10.1038/nrcardio.2016.183
36. Jandhyala S.M., Talukdar R., Subramanyam C. et al. Role of the normal gut microbiota. World J. Gastroenterol, 2015, vol. 21, pp. 8787–8803. DOI: 10.3748/wjg.v21.i29.8787